Biotechnology

IN8bio

IN8bio released FY2025 9 Months earnings on November 6, 2025 (EST), with actual revenue of USD 0 and actual EPS of USD -4.0804

IN8bio released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.8493 (forecast USD -1.245)

IN8bio Adds Ohio State University as Clinical Trial Site

Analyst Ear Covers Healthcare Industry and Focuses on Specific Stocks

IN8bio released FY2025 Semi-Annual earnings on August 7, 2025 (EST) with actual revenue of USD 0 and EPS of USD -3.645

IN8bio released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.24 (forecast USD -1.8)

IN8bio announces patient status in phase 1 clinical trial for newly diagnosed glioblastoma

IN8bio's Experimental Drug Achieves 4-Year Remission for Glioblastoma Patient

IN8bio INB-200 I Phase Trial for GBM Shows Positive Progress

IN8bio released FY2025 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.1 (forecast USD -2)

IN8BIO Inc. Reports Reduced Net Loss in Q1 2025

IN8BIO Inc. revises security purchase agreement

Analysts Rate IN8bio as 'Buy' with a Price Target of $3.62

IN8bio released FY2024 Q4 earnings on March 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.3963 (forecast USD -2.25)

IN8bio released FY2024 earnings on March 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -17.0525 (forecast USD -16.8)

IN8bio, Inc. Launches New γδ T Cell Therapy Platform INB-600

Jones Trading Upgrades IN8bio (INAB.US) Rating to Buy with Target Price of $1.20

IN8bio released FY2024 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.4923 (forecast USD -4.9)

IN8bio released FY2024 9 Months Earnings on November 12 (EST) with actual revenue of USD 0 and EPS of USD -16.2288

IN8BIO Announces Clinical Pipeline Prioritization and Layoffs

Luminar Tech

Novabay Pharmac

Mint Incorporation

Autozi Internet Tech Global

GD Culture

Impact BioMedical

Tradr 2X Long FLY Daily ETF

Leverage Shares 2X Long CRWV Daily ETF

T-REX 2X Long CRWV Daily Target ETF

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap